Business Wire

Laserfiche Joins the Boomi Technology Partner Program, Supporting the Automated, Connected Enterprise

22.2.2023 17:00:00 EET | Business Wire | Press release

Share

Laserfiche — the leading SaaS provider of intelligent content management and business process automation — today announced a partnership with Boomi, a leading provider of integration platform as a service known for its speed, ease-of-use, and low total cost of ownership. Through this partnership, organizations can simplify integrations between Laserfiche's robust content services platform and on-premises and cloud applications such as Salesforce, Workday, and Smartsheet using Boomi’s connectors to over 1,500 applications.

“Today’s connected enterprise is built on a robust technology infrastructure, which requires a centralized system to collect and monitor process data, paired with a simplified integration strategy,” said David Everson, Laserfiche’s senior director of strategic solutions. “Laserfiche is excited to bring a proven system for data centralization and process automation to the Boomi ecosystem, enabling more speed, greater agility and stronger security in our customers’ integrations.”

Laserfiche supports organizations in building end-to-end automated solutions that boost productivity, scale with growth and deliver digital-first customer experiences. Laserfiche customers can now take advantage of the enterprise content management (ECM) platform’s Boomi-powered connectors to mission-critical line-of-business applications accelerate integration deployment, more easily manage integration lifecycles and access organization-wide data analytics. The Laserfiche and Boomi partnership is enabling customers to configure and expedite solutions such as:

  • Streamlined recruiting and new employee onboarding to move candidates through the hiring process quickly
  • Sending/retrieving data to/from popular storage and databases for more flexible data queries and reporting
  • Streamlined invoice processing to gain real-time visibility into accounts payable
  • Syncing client updates to provide the business with a more holistic view of the client
  • Simplified authentication for secure connections to applications

According to The Forrester Wave™: Enterprise iPaaS, Q4 2021, “As more organizations embrace cloud-native, applications and data are more distributed than ever before. Delivering those user experiences and digital business capabilities requires an integration platform that stitches together the ever-growing number of distributed apps and data. Furthermore, the pandemic and quarantines accelerated the need for business process automation and has squeezed IT beyond what it can deliver. In response, organizations are embracing citizen iPaaS as a tool in their business process automation strategy.”

The Boomi Technology Partner Program includes enterprise software companies across applications such as CRM, ERP, HRIS and business intelligence, as well as across industries including government, education, financial services, healthcare and manufacturing. Boomi provides organizations with greater scalability and greater control over data orchestration between application transactions, allowing connectivity to scale as organizations adopt a wider range of solutions.

“We are excited to have Laserfiche as part of our Technology Partnership Program,” said Reggie Penn, global head of technology alliances at Boomi. “A leader in the enterprise content management space, Laserfiche is a solid addition to our profile of partners that offer real solutions that help organizations solve their biggest challenges. The collaboration between Laserfiche and Boomi positions our mutual customers to meet the growing demand for integrations and keep up with the rapid pace of innovation.”

Learn more about the Laserfiche and Boomi partnership by visiting the Laserfiche website.

About Laserfiche

Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through powerful workflows, electronic forms, document management and analytics, the Laserfiche® platform accelerates how business gets done, enabling leaders to focus on growth across the enterprise.

Laserfiche pioneered the paperless office with enterprise content management. Today, Laserfiche’s cloud-first development approach incorporates innovations in machine learning and AI to enable organizations in more than 80 countries to transform into digital businesses. Customers in every industry — including government, education, financial services, healthcare and manufacturing — use Laserfiche to boost productivity, scale their business and deliver digital-first customer experiences.

Laserfiche employees in offices around the world are committed to the company’s vision of empowering customers and inspiring people to reimagine how technology can transform lives.

Connect with Laserfiche:

Laserfiche Blog | Twitter | LinkedIn | Facebook

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Linda Domingo
Director, Public Relations, Laserfiche
Linda.domingo@laserfiche.com
562-988-1688 ext. 234

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release

Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi

Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release

Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob

Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release

Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati

Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release

Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F

FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 22:11:00 EEST | Press release

Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to further extend its category leadership among legal-age consumers of nicotine products. Like the flagship FDA-authorized ZYN pouches, ZYNULTRA, with its higher moisture content, is fre

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye